Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.34 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19760491 | 0.85 | P2RY14 (0.32) | FBP1P2RY2P2RY14P2RY4 | |
| SCHEMBL19760488 | 0.81 | FBP1 (0.36) | FBP1P2RY2P2RY14P2RY4AMDHD2 | |
| SCHEMBL19760432 | 0.75 | FBP1 (0.53) | FBP1P2RY2P2RY14P2RY4AMDHD2 | |
| SCHEMBL16750151 | 0.74 | FBP1 (0.43) | FBP1P2RY2P2RY14P2RY4AMDHD2 | |
| SCHEMBL19760495 | 0.74 | FBP1 (0.40) | FBP1P2RY2P2RY14P2RY4AMDHD2 | |
| SCHEMBL24814865 | 0.71 | FBP1 (0.36) | FBP1P2RY2P2RY14P2RY4AMDHD2 | |
| SCHEMBL12128761 | 0.68 | FBP1 (0.33) | FBP1P2RY2P2RY14P2RY4 | |
| SCHEMBL18194410 | 0.67 | FBP1 (0.39) | FBP1P2RY2P2RY14P2RY4 | |
| SCHEMBL13712214 | 0.67 | FBP1 (0.39) | FBP1P2RY2P2RY14P2RY4 | |
| SCHEMBL10295575 | 0.66 | FBP1 (0.53) | FBP1P2RY2P2RY14P2RY4AMDHD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180002368-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002368-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NSUN2, NSUN3, RNGTT | FBP1 3587/4885P2RY2 3747/4885P2RY14 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.